NCT03402919 Comprehensive Assessment of Neurodegeneration and Dementia
| NCT ID | NCT03402919 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University |
| Condition | Dementia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,573 participants |
| Start Date | 2016-06 |
| Primary Completion | 2023-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,573 participants in total. It began in 2016-06 with a primary completion date of 2023-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.
Eligibility Criteria
Inclusion Criteria: * Has subjective or objective cognitive impairment * Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member) * Sufficient proficiency in English or French to undertake self report and neuropsychological testing * Geographic accessibility to the study site * Must have a study partner who can participate as required in the protocol (provide corroborative information) * Up to 12 years of education * Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment Exclusion Criteria: * The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses * Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures * Symptomatic stroke within the previous year * Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure
Contact & Investigator
Michael Borrie, MD
STUDY DIRECTOR
Western University
Frequently Asked Questions
Who can join the NCT03402919 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03402919 currently recruiting?
Yes, NCT03402919 is actively recruiting participants. Contact the research team at howard.chertkow@mcgill.ca for enrollment information.
Where is the NCT03402919 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada, Vancouver, Canada, Victoria, Canada and 11 additional locations.
Who is sponsoring the NCT03402919 clinical trial?
NCT03402919 is sponsored by McGill University. The principal investigator is Michael Borrie, MD at Western University. The trial plans to enroll 1,573 participants.